For many European medical device and IVD manufacturers, regulatory interaction often happens at defined checkpoints. Under the EU MDR or IVDR, communication with notified bodies typically becomes most intensive once documentation is ready for review and conformity assessment is approaching.
When approaching the US market, however, the regulatory dynamic is somewhat different.
The FDA encourages earlier dialogue during device development. One of the most effective ways to engage with the agency at these earlier stages is through the Q-Submission (Q-Sub) program.
Rather than waiting until a submission is complete, companies can request feedback from the FDA while development plans are still taking shape. This allows manufacturers to confirm regulatory expectations, align testing strategies, and refine clinical plans before significant resources are committed.
For many EU-based companies entering the US market, this proactive interaction with the regulator can be both unfamiliar and highly valuable.
What is the FDA Q-Submission program?
The Q-Submission program provides a structured mechanism for companies to request feedback and meetings with the FDA regarding medical device and IVD development.
The most commonly used type is the Pre-Submission (Pre-Sub). Through a Pre-Sub, manufacturers can present their development strategy and ask specific questions about regulatory expectations.
This interaction allows the FDA to provide feedback before companies commit significant resources to testing, clinical studies, or regulatory submissions.
Rather than guessing how the FDA might interpret certain requirements, companies can align their development plans directly with the agency.
Why early FDA interaction matters
Regulatory uncertainty can create significant delays and costs during device development. If testing strategies, clinical study designs, or regulatory pathways are misaligned with FDA expectations, companies may need to repeat work later in the process.
Q-Submissions help reduce this risk by enabling manufacturers to discuss key topics early. These may include regulatory pathway selection, performance testing strategies, clinical evidence expectations, or usability considerations.
For startups and growing companies in particular, early regulatory clarity can significantly improve planning and resource allocation.
When should a company consider a Q-Submission?
A Q-Submission can be useful at several stages of development. Companies often request FDA feedback when determining the most appropriate regulatory pathway, designing clinical studies, or defining validation and verification strategies.
For example, manufacturers may want confirmation that their proposed testing program will support a 510(k) submission, or that their clinical study endpoints are appropriate for demonstrating safety and performance.
In these situations, a Pre-Sub meeting can provide valuable direction and prevent costly adjustments later.
Making Q-Submissions effective
While the Q-Submission program is highly valuable, its effectiveness depends on preparation. The FDA expects companies to present clear questions, structured background information, and well-defined development plans.
A successful Pre-Sub does not simply ask open-ended questions. Instead, it outlines the proposed approach and requests targeted feedback on specific aspects of the strategy.
Well-prepared Q-Submissions often lead to more productive discussions and clearer regulatory guidance.
A strategic tool for startups and international companies
For startups and companies outside the United States, the FDA regulatory environment can feel complex and unfamiliar. Q-Submissions provide an opportunity to build understanding early and establish a constructive dialogue with the agency.
This proactive approach helps companies move forward with greater confidence and reduces the likelihood of unexpected regulatory obstacles.
In many cases, a well-timed Pre-Sub can save months of development time and significant costs.
How MDS can support your FDA strategy
At MDS, we support medical device and IVD manufacturers in planning and preparing FDA Q-Submissions.
Our role includes helping define the regulatory strategy, preparing structured Pre-Sub documentation, formulating clear questions for FDA feedback, and supporting companies through the interaction process.
By combining regulatory insight with practical development experience, we help ensure that FDA engagement supports efficient and predictable product development.
Should you wish to know more about how our services can support your market entry, you can contact us at Kristian@mdsdenmark.dk or schedule a consultation via Book a Meeting.